Mechanistic Projection of First-in-Human Dose for Bispecific Immunomodulatory P-Cadherin LP-DART: An Integrated PK/PD Modeling Approach

Clinical Pharmacology and Therapeutics

Volumn 100, Issue 3, 2016, Pages 232-241

  Chen, X ^a   Haddish Berhane, N ^a,b   Moore, P ^c   Clark, T ^a   Yang, Y ^c   Li, H ^c   Xuan, D ^a   Barton, H A ^a   Betts, A M ^a   Barletta, F ^a  

^a PFIZER INC   (United States)

^b Johnson and Johnson Pharmaceutical Res and Dev   (United States)

^c Analytical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD3 ANTIGEN; IMMUNOMODULATING AGENT; P CADHERIN LP DART; UNCLASSIFIED DRUG; CADHERIN; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR;

ARTICLE; CALCULATION; CANCER IMMUNOTHERAPY; CD3+ T LYMPHOCYTE; DRUG EFFICACY; HUMAN; MODEL; NONHUMAN; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; TUMOR CELL; ANIMAL; BIOAVAILABILITY; BIOLOGICAL MODEL; BIOSYNTHESIS; CYTOTOXICITY TEST; DOSE RESPONSE; FEMALE; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; T LYMPHOCYTE;

ANIMALS; BIOLOGICAL AVAILABILITY; CADHERINS; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84988952975     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.393     Document Type: Article

References (28)

1. Mellstedt, H. Monoclonal antibodies in human cancer. Drugs Today 39 (suppl. C), 1–16 (2003).
2. Chames, P., Van Regenmortel, M., Weiss, E. & Baty, D. Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 157, 220–233 (2009).
3. May, C., Sapra, P. & Gerber, H.-P. Advances in bispecific biotherapeutics for the treatment of cancer. Biochem. Pharmacol. 84, 1105–1112 (2012).
4. Bighin, C., Pronzato, P. & Del Mastro, L. Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients. Future Oncol. 9, 955–957 (2013).
5. ®) antibody construct blinatumomab as a potential therapy. Int. Immunol. 27, 31–37 (2015).
6. Lameris, R. et al. Bispecific antibody platforms for cancer immunotherapy. Crit. Rev. Oncol. Hematol. 92, 153–165 (2014).
7. Paredes, J. et al. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin. Cancer Res. 11, 5869–5877 (2005).
8. Trapani, J.A., Voskoboinik, I. & Jenkins, M.R. Perforin-dependent cytotoxicity: ‘Kiss of death’ or prolonged embrace with darker elocation-idnseque11es? OncoImmunology 4, e1036215 (2015).
9. Voskoboinik, I., Whisstock, J. C. & Trapani, J.A. Perforin and granzymes: function, dysfunction and human pathology. Nat. Rev. Immunol. 15, 388–400 (2015).
10. Root, A.R. et al. Development of PF-06671008, a highly potent anti-P-cadherin/anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer. Antibodies 5, 6 (2016).
11. Paredes, J. et al. P-cadherin expression in breast cancer: a review. Breast Cancer Res. 9, 214 (2007).
12. Vieira, A.F. & Paredes, J. P-cadherin and the journey to cancer metastasis. Mol. Cancer 14, 178 (2015).
13. Soler, A.P., Russo, J., Russo, I.H. & Knudsen, K.A. Soluble fragment of P-cadherin adhesion protein found in human milk. J. Cell. Biochem. 85, 180–184 (2002).
14. Lowe, P.J., Hijazi, Y., Luttringer, O., Yin, H., Sarangapani, R. & Howard, D. On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica 37, 1331–1354 (2007).
15. Ryan, P. In vitro MABEL approach for nonclinical safety assessment of MEDI-565 (MT111). Altex Proceedings, 1/12, Proceedings of WC8, 85–87 (2012).
16. Agoram, B.M. Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics. Br. J. Clin. Pharmacol. 67, 153–160 (2009).
17. Muller, P.Y., Milton, M., Lloyd, P., Sims, J. & Brennan, F.R. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr. Opin. Biotechnol. 20, 722–729 (2009).
18. Deng, R., Iyer, S., Theil, F.P., Mortensen, D.L., Fielder, P.J. & Prabhu, S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? mAbs 3, 61–66 (2011).
19. Ling, J., Zhou, H., Jiao, Q. & Davis, H.M. Interspecies scaling of therapeutic monoclonal antibodies: initial look. J. Clin. Pharmacol. 49, 1382–1402 (2009).
20. Lindstedt, S.L. & Schaeffer, P.J. Use of allometry in predicting anatomical and physiological parameters of mammals. Lab. Anim. 36, 1–19 (2002).
21. Kagan, L. Pharmacokinetic modeling of the subcutaneous absorption of therapeutic proteins. Drug Metab. Dispos. 42, 1890–1905 (2014).
22. Thurber, G.M. & Wittrup, K.D. Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res. 68, 3334–3341 (2008).
23. Haller, C.A., Cosenza, M.E. & Sullivan, J.T. Safety issues specific to clinical development of protein therapeutics. Clin. Pharmacol. Ther. 84, 624–627 (2008).
24. Reigner, B.G. & Blesch, K.S. Estimating the starting dose for entry into humans: principles and practice. Eur. J. Clin. Pharmacol. 57, 835–845 (2002).
25. Betts, A.M. et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J. Pharmacol. Exp. Ther. 333, 2–13 (2010).
26. Bleeker, W.K. et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J. Immunol. 173, 4699–4707 (2004).
27. Lameris, R. et al. Bispecific antibody platforms for cancer immunotherapy. Crit. Rev. Oncol. Hematol. 92, 153–165 (2014).
28. Duff, G. Expert Scientific Group on Phase One Clinical Trials: Final Report. Department of Health, London, UK (2006).